Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
KYMRthis companyKymera Therapeutics, Inc.	$134.33	-21.09×	4.16×	167.51×	-20.76×	-99.8%	100.0%	-891.3%	-794.4%	-19.7%	-20.9%	-3.6%	0.05×	0.91×	-1,403.21×	10.47×	0.0%	4	41.46	1	C-
ARVNArvinas, Inc.	$6.52	-9.27×	1.77×	2.93×	-8.44×	-1590.9%	98.0%	-43.8%	-30.8%	-18.6%	-19.9%	-35.8%	0.02×	1.78×	0×	4.92×	0.0%	3	0.86	3	B-
CCCCC4 Therapeutics, Inc.	$3.12	-1.5×	0.62×	4.4×	-1.4×	-187.2%	77.8%	-290.7%	-292.1%	-40.9%	-31.4%	-62.7%	0.23×	0.14×	0×	7.81×	0.0%	3	-1.03	2	C
GLUEMonte Rosa Therapeutics, Inc.	$10.46	-26.58×	4.41×	8.31×	-29.87×	222.9%	93.2%	-43.8%	-31.2%	-16.6%	-13.6%	-2.7%	0.17×	2.89×	0×	6.12×	0.0%	2	1.69	2	C+
NRIXNurix Therapeutics, Inc.	$15.81	-5.54×	2.72×	17.45×	-5.2×	-213.0%	77.5%	-340.2%	-314.9%	-49.1%	-47.3%	-18.0%	0.1×	0.78×	0×	7.02×	0.0%	7	9.1	4	A-
Peer median	—	-7.4×	2.25×	6.36×	-6.82×	-200.1%	85.5%	-167.3%	-161.7%	-29.8%	-25.7%	-26.9%	0.14×	1.28×	0×	6.57×	0.0%	3	1.28	3	—